# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of applic...
Innocan Pharma's 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strateg...
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, rep...
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has closed the second and final tranche of its previously anno...
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporatio...
Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug...